THE GLOBAL 5G LANDSCAPE: An inside look at leading 5G markets, key players, and how they are defining the future of connectivity
- The next generation of wireless is here, and several countries are locked in a fierce battle for the top spot in global 5G development.
- Telecoms in 18 countries will roll out 5G networks by the end of this year, and by 2020 over one-fifth of the world's countries will have launched 5G services.
- The report compiles 5G snapshots of the three countries, with each providing an overview of the market's telecoms space and details on what is contributing to — or hindering — its development.
- We look at the notable telecoms in each geography and identify their 5G launch efforts, as well as discuss what the opportunities are for each company.
- But however you decide to acquire this report, you've given yourself a powerful advantage in your understanding of the fierce global 5G battle.
Coronavirus live updates: US soldier based in South Korea tests positive
- A U.S. soldier stationed at Camp Carroll in South Korea has tested positive for the new coronavirus — marking the first time an American service member has been infected, according to the United States Forces Korea (USFK).
- China's National Health Commission reported 406 new confirmed cases, and an additional 52 deaths, as of Feb. 25.
- South Korea reported a jump of 169 new cases, bringing the country's total to 1,146 infected, according to the country's Centers for Disease Control and Prevention on Wednesday morning.
- Iran's health ministry on Tuesday confirmed 15 deaths from the coronavirus, the most fatalities of any country outside of China, where the deadly illness originated.
- Health and Human Services Secretary Alex Azar added: "We can't hermetically seal off the United States." Azar confirmed four new cases of the virus from repatriated cruise ship passengers, bringing the total in the U.S. to 57.
Wall Street analysts are standing by these stocks in correction territory, betting on a rebound
- The coronavirus-driven market sell-off knocked hundreds of stocks from their recent highs but Wall Street is still betting on a handful of names at correction levels that can recover and rally from here.
- Got a confidential news tip?
- We want to hear from you.
- Get this delivered to your inbox, and more info about our products and services.
- Data is a real-time snapshot *Data is delayed at least 15 minutes.
- Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Dow tumbles nearly 900 points as coronavirus fears continue
- New York (CNN Business) - US markets plummeted for the second straight day Tuesday, adding to Monday's sharp losses as news about the spread of coronavirus gripped jittery investors.
- In a speech at a conference on Tuesday, Federal Reserve Vice Chairman Richard Clarida said that the central bank is closely monitoring the Coronavirus's spread and its economic impact, adding that it is too early to speculate about its effects in detail.
- News of a sudden increase in cases in Italy and South Korea tanked global markets on Monday, with the Dow plunging more than 1,000 points -- something it has only done twice before in history, both times in February 2018.
- US and global oil benchmarks also fell further on the expectation of lower demand for energy in a coronavirus-inspired economic downturn.
Dow futures bounce slightly as Wall Street attempts comeback from monster 2-day slide
- Stock futures were up in overnight trading after stocks' worst two-day rout in more than four years amid heightened concern the coronavirus will upend global economic growth.
- Futures bounced initially Monday evening before the market fell again on Tuesday.
- Stocks plunged for a second day on Tuesday, with the Dow tumbling 879 points, bringing its two-day losses to nearly 1,900 points.
- Meanwhile, the yield on the benchmark 10-year Treasury note fell to a record low of 1.31% on Tuesday as coronavirus fears raised concerns about global economic growth and sent investors scrambling into the safety of U.S. government bonds.
- The VIX, a measure of the 30-day implied volatility of U.S. stocks, crossed 30 at its session high on Tuesday as coronavirus fears rattled the markets.
- Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Woolworths profit marred by wage repayments
- Woolworths' net profit fell 7.7 per cent to $887 million in the December-half after Australia's largest retailer booked $80 million in wage remediation repayments to staff and incurred $51 million in one-off costs ahead of the planned demerger of its drinks business.
- Before one-off costs, net profit from continuing operations rose 8.5 per cent to $979 million, underpinned by solid profit growth from Woolworths' Australian and New Zealand supermarkets and Endeavour Drinks and as BIG W returned to profit for the first time since 2016.
- To date, about $78 million including interest and superannuation has been repaid, including $69 million in the December half, to affected former and current Woolworths Supermarkets and Metro salaried store team members, covering the initial two years of review (2018 and 2019).
FANG stocks shed $177 billion in just two days as coronavirus fears roil markets
- Even the most popular technology stocks have been hammered as coronavirus fears slam global markets.
- Shares of the so-called FANG stocks, including Facebook, Amazon, Netflix, and Google parent company Alphabet, shed a combined $177 billion in market capitalization in just two days as coronavirus fears slammed global markets.
- Each of the technology giants pared losses on Monday and Tuesday when global stocks fell for two days in a row.
- On Tuesday, Alphabet shed the most in market capitalization, losing roughly $24 billion in value on a 2.5% fall.
- Neftlix was the smallest loser, erasing about $4 billion after falling 2.4%.
- The Dow Jones Industrial Average lost more than 1,900 points over two days, while the S&P 500 shed about 6% and posted its worst day since February 2018 on Monday.
- The market rout was spurred by an uptick in coronavirus cases and deaths outside of China, where the disease originated.
US health officials say human trials on coronavirus vaccine to start in 6 weeks
- Human trials testing a potential vaccine for the COVID-19 coronavirus are expected to begin in six weeks, U.S. health officials announced Tuesday.
- Developing, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take months or even years, global health experts say.
- Earlier in the day, the Centers for Disease Control and Prevention outlined what schools and businesses will likely need to do if the COVID-19 virus becomes an epidemic outbreak in the U.S. The CDC late Monday confirmed 53 cases in the U.S., a majority of which came from passengers repatriated from the Diamond Princess cruise ship that was quarantined off the coast of Japan.
- Later Tuesday, U.S. health officials said the outbreak will likely become a global pandemic.
Trump spent the past 2 years slashing the government agencies responsible for handling the coronavirus outbreak
- President Donald Trump spent much of Tuesday reassuring the public that the coronavirus is under control.
- Fears of a pandemic come after the Trump administration spent the past several years gutting the very government programs that are tasked with combatting such a crisis.
- In 2018, for instance, the CDC cut 80% of its efforts to prevent global disease outbreaks because it was running out of money.
- The Trump administration recently requested $2.5 billion in emergency funds — $1.25 billion in new funding and $1.25 billion to be diverted from other federal programs — to aid in preparing and responding to coronavirus cases in the US.
- The economic consequences of an unaddressed outbreak would dwarf US spending on efforts to control it, Marc Lipsitch, an epidemiologist and the director of the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health, told Insider.
Coronavirus: FDA says it's monitoring the market for potential drug shortages, fraudulent treatment claims
- The U.S. Food and Drug Administration said Tuesday the agency is monitoring the market for potential drug shortages and fraudulent treatment claims as the coronavirus outbreak places a pause on its product inspections in China.
- The FDA has identified about 20 drug products that either solely source their active ingredients or produce finished drug products in China and has contacted their manufacturers to see if they have experienced any supply issues, FDA spokesperson Stephanie Caccomo said in a statement.
- The FDA also asked them to evaluate their entire supply chains, including ingredients and other components manufactured in China, although no firm has reported a shortage as of now.
- At this time, over 60% of FDA-regulated products imported from China are medical devices and 20% are housewares, the FDA said.